Drug Utilization Review (DUR) is designed to improve the quality of pharmaceutical care by ensuring that prescriptions are appropriate, medically necessary and unlikely to result in adverse medical outcomes. Medicaid’s DUR program includes prospective, online and retrospective review as well as use of standards developed by the National Council for Prescription Drug Programs (NCPDP). A board comprised of physicians and pharmacists provides guidance to Agency staff.
| 2021 Meetings |
January 27, 2021 |
April 28, 2021 DUR Board Summary |
|
|
| 2020 Meetings |
January 22, 2020 |
April 22, 2020
Canceled |
July 22, 2020 |
October 28, 2020 |
| 2019 Meetings |
January 23, 2019
Opioids Presentation |
April 24, 2019
|
July 24, 2019 |
October 23, 2019 |
| 2018 Meetings |
January 24, 2018 |
April 25, 2018
Opioids Presentation |
July 25, 2018 |
October 24,
2018
|
| 2017 Meetings |
January 25, 2017 |
April 26, 2017 |
July 26, 2017 |
October 25,
2017 |
| 2016 Meetings |
January 27, 2016 |
April 27, 2016
|
July 27, 2016 |
October 26, 2016 |